Welcome to our dedicated page for DAMORA THERAPEUT news (Ticker: DMRA), a resource for investors and traders seeking the latest updates and insights on DAMORA THERAPEUT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DAMORA THERAPEUT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DAMORA THERAPEUT's position in the market.
Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards are non-qualified stock options for an aggregate of 57,500 shares, 10-year term, exercise price $25.66 per share.
Options vest 25% after one year then monthly over 36 months and are governed by the 2022 Inducement Plan and individual option agreements.
Damora Therapeutics (NASDAQ: DMRA) announced inducement equity grants tied to recent hires and its new President and CEO, Jennifer Jarrett, on March 24 and March 30, 2026. The company granted non-qualified options totaling 74,000 shares to four non-executive hires at $23.05, with a 10-year term.
Ms. Jarrett received 500,000 RSUs and non-qualified options to purchase 1,500,000 shares at an exercise price of $25.50. Options vest 25% after one year, then monthly over 36 months; RSUs vest annually over four years. Grants were approved under Nasdaq Listing Rule 5635(c)(4) and subject to Damora's 2022 Inducement Plan and award agreements.
Damora Therapeutics (NASDAQ: DMRA) appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and added biotech leaders Cameron Turtle and Mike Landsittel to the Board. Peter Harwin was named Chairman. Management changes accompany a focus on advancing lead program DMR-001 and portfolio development.
Damora Therapeutics (NASDAQ: DMRA) reported full-year 2025 results and corporate milestones on March 19, 2026. The company completed acquisition of mutCALR-focused assets, raised gross proceeds of approximately $285 million (private) and $316 million (public), and holds about $535 million in cash as of February 28, 2026. Damora expects an IND/CTA for lead candidate DMR-001 by mid-2026 and two proof-of-concept datasets beginning mid-2027.
2025 results include R&D expense of $26.9M, G&A of $9.7M, and a net loss of $209.8M largely driven by a $174.3M acquired in-process R&D charge.